首页> 美国卫生研究院文献>Arthritis Research >Biologic activity and safety of belimumab a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus

【2h】

Biologic activity and safety of belimumab a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus

机译：贝利木单抗（一种中和性抗B淋巴细胞刺激物（BLyS）单克隆抗体）的生物学活性和安全性：系统性红斑狼疮患者的I期试验

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

IntroductionThis trial evaluated the safety, biologic activity, and pharmacokinetics of belimumab, a fully human monoclonal antibody that inhibits the biologic activity of the soluble form of the essential B-cell survival factor B-lymphocyte stimulator (BLyS) in patients with systemic lupus erythematosus (SLE).

机译：简介该试验评估了belimumab的安全性，生物学活性和药代动力学，belimumab是一种完全的人类单克隆抗体，可抑制系统性红斑狼疮患者中必不可少的B细胞存活因子B淋巴细胞刺激物（BLyS）的可溶性形式的生物活性。 SLE）。

著录项

期刊名称 Arthritis Research
作者
Richard Furie; William Stohl; Ellen M Ginzler; Michael Becker; Nilamadhab Mishra; Winn Chatham; Joan T Merrill; Arthur Weinstein; W Joseph McCune; John Zhong; Wendy Cai; William Freimuth;
展开▼
作者单位

展开▼
年(卷),期 2008(10),5
年度 2008
页码 R109
总页数 15
原文格式 PDF
正文语种
中图分类外科学;
关键词

相似文献

外文文献
中文文献
专利

1. Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus [J] . Richard Furie, William Stohl, Ellen M Ginzler, Arthritis Research . 2008,第5期

机译：贝利木单抗（一种中和性抗B淋巴细胞刺激物（BLyS）单克隆抗体）的生物学活性和安全性：系统性红斑狼疮患者的I期试验
2. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus? [J] . Richard Furie, Michelle Petri, Omid Zamani, Arthritis & Rheumatism . 2011,第12期

机译：在系统性红斑狼疮患者中，belimumab（一种抑制B淋巴细胞刺激剂的单克隆抗体）的III期随机，安慰剂对照研究？
3. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. [J] . Furie R, Petri M, Zamani O, Arthritis and Rheumatism . 2011,第12期

机译：在系统性红斑狼疮患者中，belimumab是抑制B淋巴细胞刺激剂的单克隆抗体，其III期随机，安慰剂对照研究。
4. Serum Levels of Leptin in Patients with Systemic Lupus Erythematosus: Correlated with Lupus Activity [C] . XU Ting, JIN Ou-yang, ZHAO Sheng-nan, International Forum on Progress on Post-Genome Technologies(5'IFPT); 20070910-11; Suzhou(CN) . 2007

机译：系统性红斑狼疮患者血清瘦素水平：与狼疮活动相关
5. The effect of nutrition counseling using patient-centered counseling methods on nutrient intake in patients with systemic lupus erythematosus (SLE) [D] . Tzakas, Sotiria. 2012

机译：使用以患者为中心的咨询方法进行的营养咨询对系统性红斑狼疮（SLE）患者营养摄入的影响
6. A Phase 3 Randomized Placebo-Controlled Study of Belimumab a Monoclonal Antibody That Inhibits BLyS in Patients With Systemic Lupus Erythematosus [O] . Richard Furie, Michelle Petri, Omid Zamani, -1

机译：一项3期随机安慰剂对照研究贝利木单抗单克隆抗体抑制BLys的在例系统性红斑狼疮
7. Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus [O] . 2008

机译：贝利木单抗（一种中和性抗B淋巴细胞刺激物（BLyS）单克隆抗体）的生物学活性和安全性：系统性红斑狼疮患者的I期试验

Biologic activity and safety of belimumab a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus

摘要

著录项

相似文献

相关主题

期刊订阅